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3 
Abstract 87 
 88 
Background: Higher cardiorespiratory fitness (CRF) is associated with lower morbidi-89 
ty and mortality in patients with coronary heart disease (CHD). The mechanisms for 90 
this are not fully understood. A more favourable cardiometabolic risk factor profile 91 
may be responsible, however few studies have comprehensively evaluated cardi-92 
ometabolic risk factors  in relation to CRF, among patients with CHD.  93 
 94 
Objective: To explore differences in cardiometabolic risk and 5-year all-cause mortal-95 
ity risk in patients with CHD who have low, moderate, and high levels of CRF.   96 
 97 
Methods: Patients with CHD underwent maximal cardiopulmonary exercise testing 98 
(CPET), echocardiogram, carotid intima-media thickness measurement, spirometry, 99 
and dual X-ray absorptiometry assessment. Full blood count, biochemical lipid pro-100 
files, high sensitivity (hs)- C-reactive protein and NT-proBNP were analysed. Pa-101 
tients were defined as having low, moderate, or high CRF based on established 102 
prognostic thresholds.  103 
 104 
Results: 70 patients with CHD (age 63.1 ± 10.0 years, 86% male) were recruited. 105 
Patients with low CRF had a lower ventilatory anaerobic threshold, peak oxygen 106 
pulse, post-exercise heart rate recovery and poor ventilatory efficiency. The low CRF 107 
group also had higher NT pro-BNP, hs-CRP, non-fasting glucose concentrations and 108 
lower haemoglobin and haematocrit. Five-year mortality risk (CALIBER risk score) 109 
was also greatest in the lowest CRF group (14.9%).  110 
 111 
4 
Conclusion: Practitioners should interpret low CRF as an important clinical risk factor 112 
associated with adverse cardiometabolic health and poor prognosis.  113 
 114 
Study registry; researchregistry.com (researchregistry3548). 115 
 116 
Key Words: Coronary Heart Disease, Cardiac Rehabilitation, Cardiometabolic Health, Exercise Train-117 
ing, Atherosclerosis, VO2peak, Maximal Cardiopulmonary Exercise Testing, Caliber 5-year risk  118 
 119 
 120 
 121 
Key Points 122 
1. Low cardiorespiratory fitness is associated with the poorest cardiometabolic 123 
health in patients with coronary heart disease. 124 
2. Five year risk of all-cause death, and NT-proBNP are highest amongst coro-125 
nary heart disease patients with the lowest cardiorespiratory fitness, even 126 
when left ventricular ejection fraction is preserved. 127 
Longer-term, or higher intensity exercise-based cardiac rehabilitation pro-128 
grammes that closely monitor cardiovascular risk factors, may be warranted 129 
for coronary heart disease patients who have low cardiorespiratory fitness. 130 
 131 
 132 
 133 
 134 
 135 
 136 
 137 
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Background 138 
 139 
Cardiorespiratory fitness (CRF) or VO2peak predicts all-cause and cardiovascular 140 
(CV) mortality in patients with coronary heart disease (CHD) (1-3). We have shown 141 
that in patients with CHD, low CRF confers the highest mortality risk (54%) over a 142 
14-year period when compared to those categorised as having moderate (31%) or 143 
high CRF [17%] (4). Improvements in CRF resulting from exercise-based cardiac re-144 
habilitation (CR) may reduce mortality in patients who have low CRF (4-6).  145 
 146 
Whilst higher CRF is a strong predictor of better survival outcomes, the mechanisms 147 
responsible for this association are not fully understood. Few studies have compre-148 
hensively profiled the cardiometabolic health status of patients with CHD in relation 149 
to established CRF fitness categories. Higher all-cause mortality in patients with 150 
CHD may not be entirely attributable to older age, cardiovascular disease (CVD) se-151 
verity, and more co-morbidities (7). Unidentified and potentially treatable cardiomet-152 
abolic risk factors may cause the divergence in mortality rates observed between pa-153 
tients with high and low CRF.  154 
 155 
Biomarkers of cardiac dysfunction, inflammation, cardiac autonomic function, arterial 156 
plaque status, renal function, blood oxygen carrying capacity, and metabolic control 157 
have received little attention in relation to CRF in patients with CHD. Where limited 158 
data does exist, CRF is often reported as estimated metabolic equivalents (METS) 159 
from treadmill or cycle ergometer workloads (2, 4, 6). Fitness estimation may be in-160 
accurate in patients with CHD, could result in individual patients being inappropriate-161 
ly assigned to a specific CRF category and, attenuate any prognostic signal (8). The 162 
6 
association between cardiometabolic health and CRF should be investigated using 163 
‘gold-standard’ maximal cardiopulmonary exercise testing (CPET).  164 
 165 
This cross-sectional investigation aimed to assess differences in CV and cardiomet-166 
abolic health amongst patients with CHD when characterised as have low, moderate 167 
or high levels of CRF. We also investigated differences in estimated 5-Year risk of 168 
death using the validated CALIBER composite scoring system (9). 169 
 170 
 171 
Methods  172 
 173 
Study Design 174 
 175 
 176 
Data for this study were taken from the Cardiovascular and cardiorespiratory Adapta-177 
tions to Routine Exercise-based Cardiac Rehabilitation study (CARE CR). Ethical 178 
approval for the study was given by the Humber Bridge NHS Research Ethics Com-179 
mittee - Yorkshire and the Humber (12/YH/0278). The study is registered with re-180 
searchregistry.com (researchregistry3548). All procedures were conducted in ac-181 
cordance with the ethical standards outlined in the 1964 Helsinki declaration and its 182 
later amendments.  183 
 184 
 185 
The methodology for this study has been reported elsewhere (10). In brief, patients 186 
were recruited following a recent hospital admission and referral to CR for stable an-187 
gina, myocardial infarction (MI), coronary artery bypass graft (CABG) surgery, or 188 
elective percutaneous coronary intervention (PCI). After giving verbal consent, pa-189 
7 
tients were invited for assessment at Academic Cardiology, Castle Hill Hospital, 190 
Kingston-Upon-Hull, where written informed consent was obtained. 191 
 192 
Resting Haemodynamics, Anthropometry and Body Composition  193 
 194 
 195 
Resting heart rate (HR) was determined at the end of 15 minutes, semi-supine rest 196 
using a 12-lead ECG (GE Healthcare, Buckinghamshire, UK). Left arm brachial 197 
blood pressure was recorded using an ECG-gated automated blood pressure (BP) 198 
cuff (Tango, SunTech Medical, Eynsham, United Kingdom).  199 
 200 
Stature (cm) was measured using a Leicester Height Measure (SECA, Birmingham, 201 
United Kingdom) with patients standing, without footwear, in the Frankfort plane with 202 
their heels and head positioned to the back of the stadiometer. Waist circumference 203 
measurements were taken 1 cm above the iliac crest (11) and hip measurements 204 
were taken from the widest aspect of the buttocks using an inflexible tape measure.  205 
Both measurements were recorded in cm and a ratio of the two was calculated to 206 
determine waist to hip circumference ratio (11). 207 
 208 
Body composition was analysed using dual X-ray absorptometry [DXA] (Lunar iDXA, 209 
GE Healthcare, Buckinghamshire, UK). Total body mass (Kg), lean body mass (Kg), 210 
total fat (%), android fat (%) and android gynoid ratio were determined using the Lu-211 
nar iDXA’s integrated software. DXA-derived total body mass was used to determine 212 
body mass index (BMI; Kg.m-2). 213 
 214 
 215 
 216 
 217 
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Echocardiogram 218 
 219 
 220 
Standard 2D, M-mode echocardiogram techniques were used to determine left ven-221 
tricular (LV) function. LV ejection fraction (LVEF) was calculated using the Simpson’s 222 
method from measurements of end-diastolic and end-systolic volumes on apical 4-223 
chamber and 2-chamber 2D views, following the guidelines of Schiller and col-224 
leagues (12). LV systolic dysfunction was diagnosed if LVEF was ≤45%. 225 
 226 
Carotid-Intima-Media Thickness and Carotid Plaque Measurement 227 
 228 
Carotid intima-media thickness (C-IMT) and carotid plaque measurements were ob-229 
tained using the Panasonic CardioHealth Station (Panasonic Biomedical Sales Eu-230 
rope BV, Leicestershire, UK) which has low measurement variability (13, 14). Meas-231 
urements were taken using previously outlined methods (13) and (10) from a 1cm 232 
segment of the common carotid artery (CCA) located 1cm proximally from the carotid 233 
bifurcation. Measurements from the right and left CCA were taken in the longitudinal 234 
plane at anterior (right CCA 150°; left CCA 210°), lateral (right CCA 120°; 230°) and 235 
posterior (right CCA 90°; left CCA 270°)  angles, relative to ground. Each C-IMT 236 
measurement was determined from the average of 24 digital distance markers au-237 
tomatically placed between the intimal-medial boundaries and reported to three dec-238 
imal places. Carotid artery plaques were measured in the longitudinal plane. The 239 
largest plaque was taken as the representative measure of the patient’s carotid 240 
plaque status and reported as being either <1.0mm, ≥1.0 to <3.0mm or ≥ 3.00mm. 241 
Blood Samples 242 
 243 
 244 
Blood samples were taken from a vein at the antecubital fossa and collected in eth-245 
ylenediaminetetraacetic acid (EDTA), potassium oxalate, and serum separating 246 
9 
tubes (SST). Full blood count, (haematocrit, haemoglobin and neutrophil and lym-247 
phocyte count), and estimated glomerular filtration rate (eGFR) were analysed on the 248 
day of collection using a registered National Health Service (NHS) pathology lab 249 
(Castle Hill Hospital, Hull). A further EDTA and potassium oxalate tube were placed 250 
in a refrigerated (4°C) centrifuge at 3,000 revolutions per minute, for 15 minutes im-251 
mediately after the blood draw. Samples collected in SST tubes were allowed to clot 252 
for 30 minutes prior to being centrifuged under the same conditions. 253 
 254 
The ABX Pentra 400 biochemistry auto analyser (Horiba, Montpellier, France) was 255 
used to analyse serum triglycerides, total cholesterol, high density lipoprotein choles-256 
terol (HDL), plasma glucose, and high sensitivity C-reactive protein (hs-CRP) in du-257 
plicate. Calibration and quality controls were conducted in accordance with manufac-258 
turer’s guidelines. Low density lipoprotein (LDL) was estimated from the Friedewald 259 
equation (15).  260 
 261 
 262 
Cardiopulmonary Exercise Testing and Assessment of Physical Activity 263 
 264 
After three minutes of seated rest, CPET was conducted following the modified 265 
Bruce treadmill protocol (GE Healthcare, Buckinghamshire, UK) protocol (16) in ac-266 
cordance with established guidelines (17-20). A 12-lead ECG was monitored contin-267 
uously throughout the test. An ECG-gated automated BP measurement was record-268 
ed at the start of CPET and at the second minute of an test stage until the end of the 269 
test. RPE scores were recorded at peak exercise. HR was recorded at 1, 2, 3 and 6 270 
minutes during the passive seated recovery period.  271 
 272 
10 
Breath-by-breath gas exchange data were collected using an Oxycon Pro metabolic 273 
cart (Jaeger, Hoechburg, Germany). VO2peak was defined as the mean VO2 (ml) over 274 
the last 30 seconds of the CPET. 
 
VO2peak was adjusted for both body mass and lean 275 
(DXA-derived) body mass (ml/kg/min).  The ventilatory anaerobic threshold (VAT) 276 
was determined using the V-slope method (21) by two independent investigators. 277 
Where agreement on VAT scores was not met, the results were discussed with a 278 
third independent investigator and a consensus was reached. The VAT was using 279 
the average of the middle 5 of 7 consecutive breaths (excluding the highest and low-280 
est measures) and reported standardised to patient body mass (ml/kg/min). The ox-281 
ygen uptake efficiency slope (OUES), VE/VCO2 slope and oxygen pulse (VO2/HR) 282 
were calculated as previously described (19). Self-reported weekly physical activity 283 
levels were obtained by asking patients if they participated in either 150 minutes of 284 
moderate physical activity, 75 minutes of vigorous physical activity or, both. 285 
 286 
 287 
Determination of Cardiorespiratory Fitness Categories 288 
Patients were categorised into three groups based on their VO2peak. We converted 289 
VO2peak into metabolic equivalents (METs) by dividing by 1 MET (estimated to be 290 
equivalent to a VO2 of 3.5 ml/kg/min) to allow for easier comparisons with other stud-291 
ies. Low CRF was defined as a peak MET value of <5 for men and <4 for women; 292 
high CRF was defined as peak MET >7 for men >6 for women. These thresholds 293 
were based on previously published prognostic thresholds (4-6, 22, 23).  294 
 295 
 296 
 297 
 298 
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Prognosis - CALIBER 5-year Risk Score 299 
 300 
 301 
A 5-year risk of all-cause mortality was calculated for each patient using the compre-302 
hensive online (https://www.caliberresearch.org/model) CALIBER 5-year risk score 303 
(9). This model does not include any CRF measurements in its calculation. A full list 304 
of included variables can be found in Table 1. 5-year risk of all-cause mortality was 305 
reported as a percentage to one decimal place.  306 
 307 
 308 
Statistical Analysis 309 
 310 
 311 
Statistical analysis was performed using SPSS version 22 (IBM, New York, USA). 312 
The Shapiro-Wilk test and histograms were used to assess normality.  Categorical 313 
data are reported as percentages. Continuous normally distributed variables are dis-314 
played as mean with 95% confidence intervals (95% CI) or standard deviation (±) 315 
where specified. One-way analysis of variance (ANOVA), one-way analysis of covar-316 
iance (ANCOVA), and chi-squared analysis were used to assess differences be-317 
tween CRF groups. The only covariate considered in analysis was age as sex was 318 
used in assigning patients to their CRF category. 319 
 320 
Statistical significance was set at P<0.05. Partial eta squared (ηp2) effect sizes were 321 
used to report the magnitude of group differences. Effect sizes of 0.01, 0.06, and 322 
0.14 denoted small, moderate, and large effect sizes respectively (24). Pearson cor-323 
relations were used to assess the strength of the relationship between CRF category 324 
and CALIBER 5-year risk of death. An r value of <0.25, 0.26 to 0.50, 0.51 to 0.75, 325 
and, >0.75 were considered weak, moderate, fair and strong associations, respec-326 
tively (25).  327 
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Results 328 
 329 
 330 
Cohort Characteristics  331 
 332 
Seventy patients were recruited. Sixteen (23%) patients had sustained an ST-333 
elevation myocardial infarction (STEMI), 22 (31%) had sustained a non-STEMI, and 334 
19 (27%) had undergone elective percutaneous coronary intervention. Seven pa-335 
tients (10%) were medically managed for stable angina, and six (9%) had undergone 336 
coronary artery bypass grafting (CABG). The mean age of the cohort was 63.1 ± 337 
10.0 years (BMI: 29.2 kg.m-2 ± 4.0; 86% male). The mean LVEF was 55.0 ± 6.9%. 338 
The median time from cardiac event to consent was 54 days (range: 22 to 220). 94% 339 
of patients were seen within 90 days.  340 
 341 
Twenty-eight (40%), thirty-two (46%) and ten (14%) patients were defined as having 342 
high, moderate and low levels of CRF, respectively. CRF group characteristics are 343 
shown in Table 2. Patients with low CRF were older (p<0.001) and had a lower lean 344 
body mass than patients with moderate (p=0.029) and high CRF (p=0.002). Com-345 
pared to patients with high (p<0.001) and moderate CRF (p=0.002), patients with low 346 
CRF also had a lower android gynoid ratio, higher resting HR (high, p=0.004; low, 347 
p=0.042) and a larger proportion of patients suffering from type II diabetes (p=0.028). 348 
Medications (Table 3) were comparable across all three groups with the exception of 349 
diuretics which were more commonly prescribed to patients in the low CRF group 350 
(p=0.001).   351 
 352 
 353 
 354 
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 355 
Cardiorespiratory Fitness and Physical Activity  356 
 357 
CRF and physical activity related variables are shown in Table 4. Differences in 358 
VO2peak standardised to lean body mass, VAT, VO2/HR and exercise test duration 359 
were observed across all groups. Compared to patients with high CRF, VE/VCO2 360 
slope and OUES were both higher amongst patients in the moderate and low CRF 361 
groups. Mean LVEF was not different across the groups and was not significantly 362 
correlated with peak METs (r=0.147; p=0.224). One patient in both the low and mod-363 
erate CRF groups had a LVEF <40%. Compared to patients with high and moderate 364 
CRF, patients with low CRF had the most impaired 1-minute HR recovery, an indica-365 
tor of cardiac autonomic function. The proportion of patients who reported participat-366 
ing in either 150 minutes of moderate (p=0.011), or 75 minutes of vigorous physical 367 
activity per-week was higher in the high CRF group. 368 
 369 
Blood Biomarkers and Cardiovascular Risk 370 
 371 
Results of blood biochemical analyses are displayed in Table 5. NT-proBNP was in-372 
versely associated with CRF (r=0.414) and was highest amongst patients with low 373 
CRF. Four (40%) patients with low CRF had an NT-proBNP >400pg/ml compared to 374 
eight (25%) and one (4%) in the moderate and high CRF groups. One patient in the 375 
low CRF group without previously diagnosed chronic heart failure (CHF) had an NT-376 
proBNP result >2000pg/ml with a mildly reduced LVEF (45%), sinus rhythm and with 377 
an eGFR of 73 mL/min/1.73m2. Lipid profiles did not differ between groups. Non-378 
fasting plasma glucose concentrations in the low CRF group were higher than the 379 
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moderate CRF group (p=0.008). hs-CRP was also highest in the low CRF group. Hct 380 
and Hb differed between all groups.  381 
 382 
Carotid Intima-Media Thickness 383 
 384 
A moderate inverse correlation between left-sided C-IMT measurements and CRF 385 
was observed (r=-0.382; p=0.001) with larger plaques in the low (0.926; 95% CI 386 
0.797, 1.054; p=0.002) and moderate CRF groups (0.827; 95% CI 0.755, 0.898; 387 
p=0.011), compared to the high CRF group [0.689; 95% CI 0.612, 0.765] (Figure 1). 388 
There was no significant correlation between right sided C-IMT and CRF (r=-0.210; 389 
p-0.080). The proportion of patients with left-sided plaque score <1mm (Figure 2) in-390 
creased with each CRF group (low 10%; moderate 25%; high; 39%). The proportion 391 
of patients exhibiting large left-sided plaque scores (>3mm) decreased across each 392 
group (low 40%; moderate 16%; high; 4%; p=0.047). Patients with moderate and low 393 
CRF had incrementally higher proportions of patients with right-sided plaque scores 394 
>3mm (moderate CRF 9.4%; low CRF 30%) compared to patients in the high CRF 395 
who had no plaques >3mm (Figure 2; p=0.032).  396 
All-cause Mortality Estimation 397 
 398 
Differences in CALIBER 5-year risk (Figure 3) were observed between all groups. 399 
Estimated risk was highest in the low CRF group (14.9; 95% CI 11.4, 18.5%). The 400 
moderate group had a 9.7% 5-year risk of death (95% CI 7.7, 11.7%) whilst high 401 
CRF was associated with lowest 5-year risk of death (3.7%; 95% CI 1.6, 5.8%). 402 
There was a negative association between peak METS and CALIBER 5-year risk 403 
score (r=-0.538; r2=0.289; p=<0.001).  404 
15 
 405 
Statistical Adjustment for Age  406 
Differences in left sided mean C-IMT (p=0.274; ηp2=0.039) became non-significant 407 
following age-adjustment. Statistically significant differences for all other variables 408 
remained unaltered after statistical adjustment for age. 409 
 410 
 411 
 412 
 413 
Discussion 414 
 415 
 416 
To our knowledge, this is the first study to comprehensively profile the cardiometa-417 
bolic and CV health status of patients with CHD according to prognostically verified 418 
CRF categories (4-6, 22, 23). Patients with the lowest CRF have the poorest inte-419 
grated cardiorespiratory function and cardiometabolic health. Patients with low CRF 420 
may also have impaired autonomic function and worse CV disease severity. Low 421 
CRF was associated with the poorest CALIBER 5-year all-cause mortality risk and 422 
'high risk' status [defined as 3% annual mortality risk (26)], despite the risk model not 423 
including CRF-based measurements. The CALIBER model includes an extensive set 424 
of all-cause mortality predictor variables, including sociodemographics, CHD severity 425 
and phenotype, primary CVD risk factors, CVD and non-CVD comorbidities, psycho-426 
social factors and biomarkers.  This provides further evidence that CRF and other 427 
CPET derived variables should be treated as ‘clinical vital sign’ (27). 428 
An important finding of this study was that NT-proBNP levels and VE/VCO2 slopes 429 
were highest in the moderate and low CRF groups. This suggests a greater degree 430 
of cardiac dysfunction, ventilatory perfusion mismatch or, heightened peripheral 431 
chemoreceptor sensitivity as seen in patients with CHF (28, 29). NT-proBNP levels 432 
and VE/VCO2 slopes were higher even in the absence of significant resting LV im-433 
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pairment. It is possible that patients with CHD and low CRF have undiagnosed CHF 434 
or are in the early stages of its development. Future research is required to deter-435 
mine whether lower CRF in patients with CHD confers a greater risk of developing 436 
CHF. Closer monitoring for signs and symptoms of CHF may be needed for patients 437 
who enter CR and have low CRF.  438 
 439 
The prognostic value of a high VE/VCO2 slope and/or NT-proBNP has been well-440 
described in CHF (30-32). However, the value of VE/VCO2 slope and NT-proBNP 441 
levels have also been shown in CHD. Elevated values predict all-cause mortality 442 
(33), cardiovascular mortality (~5 year follow-up), and the development of CHF and 443 
stroke (34). High VE/VCO2 are independently associated with high NT-proBNP lev-444 
els, as well as ventricular remodelling (35). Our findings suggest that patients with 445 
both low and moderate CRF levels are at greatest risk of having such adverse health 446 
outcomes, corroborated by their higher CALIBER 5-year risk. 447 
 448 
Traditional risk factors such as angina symptoms, prior MI, atrial fibrillation, claudica-449 
tion, type II diabetes, CHF, and smoking history do not entirely explain the increased 450 
mortality risk associated with having low CRF. Physical activity participation and 451 
higher CRF have been established as important independent causative factors for 452 
recurrent events (7). In our study, patients defined as having high CRF reported par-453 
ticipating in regular physical activity and had the lowest 5-year risk of death. This 454 
was accompanied by a lower resting HR and a quicker post-exercise HR recovery, 455 
indicators of autonomic function which also carry prognostic value. Interestingly 456 
however, no differences were evident in standard anthropometric indices (BMI or 457 
waist circumference) or in DXA-derived body fat content across the CRF groups. 458 
17 
 459 
The link between cardiometabolic profile, body composition, and cardiovascular risk 460 
has been widely reported and there is often an emphasis on reducing overweight 461 
and obesity states in CR programmes. In our study, patients with higher CRF had a 462 
larger proportion of lean tissue and more favourable abdominal fat distribution. Low 463 
CRF was only associated with latent changes in body composition. Changes were 464 
not evident when assessing patients with routinely applied anthropometric tech-465 
niques, such as BMI and waist circumference. Whilst overweight patients with CHD 466 
have been reported to benefit from a better prognosis than their leaner counterparts, 467 
(36), the association between higher BMI and reduced all-cause mortality may de-468 
pend on a patients CRF. Those characterised as having low CRF appear to benefit 469 
from improved survival whilst fitter individuals do not (37, 38). Our findings (incorpo-470 
rating criterion fitness and ‘fatness’ measures) suggest that maintaining or improving 471 
CRF may help lower recurrent cardiovascular risk in patients with CHD. However, 472 
our sample is relatively small and only ten patients were identified as having a low 473 
CRF (n=10). This may increase the likelihood of statistical error (type I/type II error) 474 
when comparing CRF groups. However, many of the effect sizes (ηp2) associated 475 
with differences in cardiometabolic risk were large. Furthermore, the 95% CI indicate 476 
distinct values for many cardiometabolic variables across the CRF groups. However, 477 
further research using a larger patient cohort is required to confirm if our findings are 478 
representative of the wider CHD population. 479 
Our finding that patients with high CRF have lower CALIBER 5-year risk scores 480 
compared to patients with low and moderate CRF supports the findings of others (4, 481 
6). In these studies patients characterised as having high CRF were shown to have 482 
superior survival over a 15-year period. Barons, Turner (6) reported that within their 483 
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low CRF group, a history of MI, PCI and angina were associated with the highest risk 484 
of death. Our data do not confirm this. However, similar to our findings, Taylor et al., 485 
(4) reported that prior MI is not more prevalent amongst patients with low CRF. It is 486 
possible that size and location of MI are more likely responsible for differences in 487 
cardiac dysfunction. 488 
 489 
Patients with a high CRF also had smaller left-sided C-IMT measurements compared 490 
to patients with moderate or low CRF. This may be because patients with a high 491 
CRF also had a better cardiometabolic profile, including high levels of self-reported 492 
physical activity. Exercise training can improve cardiovascular risk factor profiles in 493 
patients with CHD (40) and attenuate C-IMT and carotid plaque progression in as 494 
little as 6 to 12 months (41, 42). It is however important to acknowledge that older 495 
age attenuated the relationship between C-IMT and CRF. 496 
 497 
Conclusion 498 
Identification of patients with low CRF and CHD appears to be an effective means of 499 
identifying those at highest cardiometabolic risk, and increased risk of 5-year all-500 
cause mortality. Exercise testing is widely applied in cardiological and CR environ-501 
ments. Longer-term, or higher intensity exercise-based CR programmes may help 502 
improve the cardiometabolic health of patients with CHD and low CRF. 503 
 504 
 505 
 506 
 507 
 508 
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List of Abbreviations 509 
ANOVA  Analysis of Variance 510 
ANCOVA  Analysis of Covariance 511 
BMI   Body Mass Index 512 
BP   Blood Pressure 513 
CABG   Coronary Artery Bypass Graft 514 
CCA   Common Carotid Artery 515 
CHD   Coronary Heart Disease 516 
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Table 1 – Variables included in the CALIBER 5-year risk score 
 606 
 607 
 608 
 609 
 610 
 611 
 612 
 613 
 614 
 615 
 616 
 617 
 618 
 619 
 620 
 621 
 622 
 623 
 624 
 625 
 626 
 627 
Categorical Variables Continuous Variables 
Sex Age 
Belongs to most deprived  quintile Total cholesterol 
CAD diagnosis and severity HDL 
Interventions (last six months) Heart rate 
Smoking status Creatinine 
Hypertension/BP lowering medication White cell count 
Diabetes Haemoglobin 
Heart failure   
Peripheral arterial disease   
Atrial fibrillation   
Stroke   
Chronic renal disease   
COPD   
Cancer   
Chronic liver disease   
Depression    
Anxiety   
CAD = Coronary Artery Disease; BP = Blood Pressure; COPD; Chronic 
Obstructive Pulmonary Disease; HDL; High Density Lipoprotein 
24 
 628 
 629 
 630 
 631 
 632 
 633 
 634 
 635 
Variable High CRF n=28 Mod CRF n=32 Low CRF n=10 Partial 
Eta 
Squared 
P-
value 
Sex (% male) 26 (93) 27 (84) 7 (70)  0.199 
Age (years) 56.3 (53.1, 59.4)*✝ 67.2 (64.3, 70.2)✝ 69.3 (64.1, 74.5)* 0.326 <0.001** 
BMI (kg.m-2) 29.0 (27.5, 30.5) 28.9 (27.5, 30.3) 30.9 (28.3, 33.4) 0.03 0.363 
Waist Circumference (cm) 101.3 (97.3, 105.4) 102.6 (98.7, 106.4) 108.1 (101.4, 114.9) 0.043 0.235 
Waist to Hip Ratio (cm) 0.96 (0.93, 0.98) 0.98 (0.95, 1.00) 0.96 (0.92, 1.01) 0.018 0.553 
Android Fat % 45.0 (42.0, 48.0) 48.0 (45.2, 50.8) 47.9 (42.9, 52.9) 0.034 0.316 
Total Fat %  35.9 (32.2, 39.6) 37.3 (33.8, 40.7) 41.1 (34.8, 47.3) 0.029 0.371 
Lean Body Mass (Kg) 55.0 (51.9, 58.1)*✝ 50.2 (47.3, 53.1)✝ 45.3 (40.1, 50.5)* 0.145 0.005** 
Android/ Gynoid Ratio 1.31 (1.24, 1.38)* 1.26 (1.20, 1.32)x 1.06 (0.95, 1.17)*x 0.182 0.001** 
 
LVEF (%) 
56.6 (54.0, 59.2) 54.3 (51.8, 56.6) 52.8 (48.5, 57.1) 0.043 0.232 
Resting HR (bpm) 56 (52, 69)* 59 (56, 63)x 67 (61, 74)*x 0.118 0.015** 
Resting SBP (mmHg) 130 (122, 137) 124 (117, 131) 138 (125, 150) 0.056 0.147 
Resting DBP (mmHg) 85 (80, 89) 82 (77, 86) 73 (65, 81) 0.083 0.055 
FEV1/FVC Ratio  0.78 (0.75, 0.81) 0.75 (0.72, 0.78) 0.75 (0.70, 0.80) 0.042 0.237 
      
Presenting Diagnosis 
     
MI 17(61) 15(47) 6(60)  0.642 
PCI 8(29) 11(34) 1(10)   
Angina 2(7) 3(9) 2(20)   
CABG 1(4) 3(9) 1(10)   
      
Past Medical History 
     
Previous MI (%) 6 (21) 6 (19) 2 (20)  0.186 
Type II Diabetes (%) 3 (12) 6 (19) 5 (50)  0.028** 
Atrial Fibrillation 0(0) 2(6) 1 (10) 
 
0.269 
Smoker 1(4) 1(3) 2(20)  0.238 
Ex-smoker 16(57) 16(50) 7(70)   
Mod = Moderate; BMI = Body Mass Index; LVEF = Left Ventricular Ejection Fraction; HR = Heart Rate; SBP –= Systolic Blood Pressure; 
DBP = Diastolic Blood Pressure; FEV1/FVC = Ratio of Forced Expiratory Volume in 1 Second to Forced Vital Capacity; MI = Myocardial 
Infarction; PCI = Percutaneous Coronary Intervention; CABG = Coronary Artery Bypass Graft 
** = Significant Group Effect; * = Significant Difference Between High CRF and Low CRF; ✝= Significant Difference Between High CRF and Moderate 
CRF; x = Significant Difference Between Mod CRF and Low CRF; + = Significantly Different from all Other Groups 
Table 2 – Patient characteristics expressed as mean (95% confidence intervals) 
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Table 3 – Number (%) of medications taken by patients 
ACE = Angiotensin Converting Enzyme 
** = Significant Group Effect; + = Significantly Different from all Other Groups 
Medication
High 
CRF 
n =28
Mod 
CRF 
n =32
Low 
CRF 
n =10
P-value
Aspirin (%) 27 (96) 31 (97) 10 (100) 0.838
Ticagrelor (%) 15 (54) 17 (53) 3 (30) 0.393
Clopidogrel (%) 10 (36) 8 (25) 3 (30) 0.665
Anti-coagulants (%) 0 (0) 1 (3) 1 (10) 0.263
Beta-Blockers (%) 24 (86) 29 (91) 7 (70) 0.266
ACE-Inhibitors (%) 19 (68) 16 (50) 7 (70) 0.291
Angiotensin Receptor 
Blockers  (%) 0 (0) 5 (16) 1 (10) 0.096
Statins  (%) 25 (89) 32 (100) 10 (100) 0.095
Diuretics (%) 1 (4) 1 (3) 5 (50) 0.001**
Calcium Chanel 
Blockers (%) 4 (14) 8 (25) 4 (40) 0.502
Nitrates (%) 2 (7) 3 (9) 3 (30) 0.233
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Variable High CRF n=28 Mod CRF n=32 Low CRF n=10 
Partial 
Eta 
Squared 
P-value 
VO2Peak (ml/kg/min) 28.5 (27.3, 29.7)+ 20.7 (19.5, 21.8)+ 14.9 (12.8, 16.9)+ - - 
VO2Peak (L/min) 2478.2 (2333.0, 2623.5)+ 1749.0 (1613.1, 1884.9)+ 1273.8 (1030.7, 1516.8)+ - - 
VO2Peak - Lean (ml/kg/min) 45.2 (43.4, 47.0)+ 34.8 (33.2, 36.5)+ 26.8 (23.8, 29.8)+ 0.670 <0.001** 
VAT (ml/kg/min) 20.7 (19.3, 22.1)+  14.6 (13.3, 15.9)+  11.2 (8.9, 13.6)+ 0.494 <0.001** 
VE/VCO2 slope 30.1 (28.2, 32.1)*✝ 37.4 (35.6, 39.2)✝ 38.5 (35.2, 41.7)* 0.354 <0.001** 
O2/HR (ml/beat) 17.0 (15.8, 18.2)+ 13.8 (12.7, 14.9)+ 11.3 (9.4, 13.3)+ 0.311 <0.001** 
OUES 2718.3 (2555.3, 2881.3)*✝ 1963.5 (1811.1, 2116.0)✝ 1699.0 (1426.2, 1971.7)* 0.485 <0.001** 
eBR (%) 30.3 (23.6, 36.9) 28.1 (22.0, 34.3) 37.0 (26.0, 48.1) 0.028 0.384 
Peak HR (bpm) 147 (141, 153)*✝ 128 (122, 134)✝ 119 (108, 129)* 0.308 <0.001** 
Peak RER 1.13 (1.09, 1.12)* 1.09 (1.05, 1.12)x 0.97 (0.91, 1.04)*x  0.181 0.001** 
Peak RPE 18 (17, 19) 18 (17, 19) 17 (15, 18) 0.072 0.083 
1 Min HR Recovery (bpm) -36 (-32, -40)* -30 (-26, -34)x -18 (-11, -25)*x 0.209 <0.001** 
2 Min HR Recovery (bpm) -54 (-50, -59)+ -45 (-40, -49)+ -32 (-25, -38)+ 0.312 <0.001** 
3 Min HR Recovery (bpm) -60 (-56, -65)+ -49 (-45, -53)+ -37 (-30, -44)+ 0.359 <0.001** 
6 Min HR Recovery (bpm) -67 (-62, -71)+ -54 (-50, -58)+ -41 (-33, -48)+ 0.377 <0.001** 
Exercise Test Duration (Secs) 963.2 (916.3, 1010.1)+ 747.8 (703.9, 791.6)+ 488.3 (409.8, 566.8)+ 0.635 <0.001** 
METs  8.1 (7.8, 8.5)+ 5.9 (5.6, 6.2)+ 4.3 (3.7, 4.8)+ - - 
Maximal CPET (%) 26 (93) 26 (81) 6 (60)   0.058 
Achieves 150 Minutes of Moder-
ate Activity Per-Week (%) 18 (64)
+
 9 (28) 5 (50)   0.011** 
Achieves 75 Minutes of Vigorous 
Activity Per-Week (%) 7 (25)
+
 1 (3) 0 (0)   0.013** 
VO2peak = Peak Oxygen Uptake; VAT = Ventilatory Anaerobic Threshold; VE/VCO2 = Ventilatory Efficiency with Respect to CO2 Elimination; O2/HR= Oxygen Pulse; 
OUES = Oxygen Uptake Efficiency Slope; eBR = Estimated Breathing Reserve; HR = Heart Rate; bpm = Beats per Minute; RER = Respiratory Exchange Ratio; RPE 
= Rating of Perceived Exertion; Secs = Seconds; METs = Metabolic Equivalents 
** = Significant Group Effect; * = Significant Difference Between High CRF and Low CRF; ✝= Significant Difference Between High CRF and Moderate CRF; x = Significant Difference 
Between Mod CRF and Low CRF; + = Significantly Different from all Other Groups 
 
 
Table 4 – Cardiorespiratory fitness and physical activity characteristics expressed as mean (95% confidence intervals)  
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NT-proBNP = N-Terminal Prohormone Brain Natriuretic Peptides; Chol = Cholesterol; LDL = Low Density Lipoproteins; 
HDL = High Density Lipoproteins; hs-CRP = High-Sensitivity C-Reactive Protein; eGF = Estimated Glomerular Filtration 
Rate 
** = Significant Group Effect; * = Significant Difference Between High CRF and Low CRF; ✝= Significant Difference Between High CRF and Moderate 
CRF; x = Significant Difference Between Moderate CRF and Low CRF; + = Significantly Different from all Other Groups 
Variable High CRF n =28 Mod CRF n =32 Low CRF n =10
Partial 
Eta 
Squared
p-value
NT-proBNP (ng/L) 86.1 (11.4, 1428.0) *✝ 217.0 (33.9, 1916.0)✝ 464.0 (26.9, 2735.0)* <0.001**
Total Chol  (mmol/L) 3.6 (3.2, 3.9) 3.7 (3.4, 4.0) 3.9 (3.3, 4.5) 0.017 0.579
LDL Chol (mmol/L) 1.7 (1.4, 1.9) 1.8 (1.6, 2.1) 1.9 (1.4, 2.3) 0.019 0.529
HDL Chol (mmol/L) 1.2 (1.0, 1.3) 1.2 (1.0, 1.3) 1.4 (1.2, 1.6) 0.052 0.176
TC/HDL Ratio 3.2 (2.9, 3.5) 3.3 (3.0, 3.6) 3.0 (2.5, 3.6) 0.01 0.713
Triglycerides (mmol/L) 1.6 (1.3, 1.9) 1.5 (1.2, 1.8) 1.4 (0.9, 2.0 0.011 0.691
Glucose (mmol/L) 5.7 (3.3, 13.8) 5.2 (4.1, 22.2)x 6.4 (5.5, 16.9 )x 0.012**
hs-CRP (mg/L) 1.4 (0.3, 2.5)* 2.8 (1.7, 3.8) 4.2 (2.3, 6.2)* 0.099 0.033**
Neutrophil/Lymphocyte 2.4 (2.1, 2.8) 2.8 (2.4, 3.1) 3.3 (2.7, 3.8) 0.084 0.052
Haematocrit (%) 0.423 (0.410, 0.435)+ 0.405 (0.393, 0.417)+ 0.376 (.355, 0.397)+ 0.18 0.001**
Haemoglobin (g/L) 145.5 (140.7, 150.2)+ 138.2 (133.7, 142.6)+ 125.6 (117.6, 133.6)+ 0.219 <0.001**
eGFR (mL/min/1.73m2) 80.2 (75.2, 85.3) 76.2 (71.4, 80.9) 71.0 (62.6, 79.4) 0.053 0.16
Table 5 – Blood biomarkers expressed as mean (95% confidence intervals)  
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Figure Title and Legends 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 - Left and right-side carotid artery plaque severity in patients with high, moderate and low cardiorespira-
tory fitness. Black bars indicate the proportion of patients with plaques <1mm, diagonal lines indicate the propor-
tion of patients with plaques between 1 and 3mm. Grey bars indicate the proportion of patients with plaques 
>3mm.  
 
Mod = Moderate; CCA = Common Carotid Artery 
Figure 3 - CALIBER 5-year all-cause mortality risk scores were incrementally higher across the three cardiorespira-
tory fitness groups.  
 
Mod = Moderate; CRF = Cardiorespiratory fitness;  
+ = Significantly Different from all Other Groups 
Figure 1 - Carotid intima-media thickness measurements in low, moderate and high cardiorespiratory fitness 
groups. Mean left-sided carotid intima-media thickness measurements (solid grey bars) were higher in the Low 
and Moderate cardiorespiratory fitness categories. Mean right-sided carotid intima-media thickness (lines) did 
not differ between groups.  
 
Mod = Moderate; CRF= Cardiorespiratory fitness * = Significant Difference Between High CRF and Low CRF; ✝= Significant Difference 
Between High CRF and Moderate CRF; 
